Federated learning with multi‐cohort real‐world data for predicting the progression from mild cognitive impairment to Alzheimer's disease

Alzheimer s & Dementia, Journal Year: 2025, Volume and Issue: 21(4)

Published: April 1, 2025

Leveraging routinely collected electronic health records (EHRs) from multiple health-care institutions, this approach aims to assess the feasibility of using federated learning (FL) predict progression mild cognitive impairment (MCI) Alzheimer's disease (AD). We analyzed EHR data OneFlorida+ consortium, simulating six sites, and used a long short-term memory (LSTM) model with averaging (FedAvg) algorithm. A personalized FL was address between-site heterogeneity. Model performance assessed area under receiver operating characteristic curve (AUC) feature importance techniques. Of 44,899 MCI patients, 6391 progressed AD. models achieved 6% improvement in AUC compared local models. Key predictive features included body mass index, vitamin B12, blood pressure, others. showed promise predicting AD by integrating heterogeneous across institutions while preserving privacy. Despite limitations, it offers potential for future clinical applications. applied record institutions. improved prediction performance, increase identified key features, such as pressure. shows effectiveness handling heterogeneity sites ensuring Personalized pooled generally performed better than global

Language: Английский

---

Myelopathic motor symptoms overlaying Parkinson’s disease

Practical Neurology, Journal Year: 2025, Volume and Issue: unknown, P. pn - 004546

Published: March 26, 2025

Parkinson’s disease (PD) may increase the risk of degenerative cervical myelopathy, causing overlaying myelopathic motor symptoms that can be challenging to identify. However, this diagnosis must not missed, given profound and lasting disability benefit surgical intervention. We describe a fortnight in which three patients with PD were admitted our inpatient movement disorders service myelopathy; each highlighting distinct learning point regarding or management. First, careful examination is crucial, clinicians should always consider myelopathy patient whose mobility has dramatically reduced. Second, need pharmacological suppression dyskinesias after surgery prevent ongoing injury promote healing. Third, medical factors, such as B12 deficiency, potential exacerbate effects, corrected.

Language: Английский

---

Parkinson's disease and gut microbiota metabolites: The dual impact of vitamins and functional amyloids

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, Journal Year: 2025, Volume and Issue: 1871(6), P. 167862 - 167862

Published: April 18, 2025

Language: Английский

---

The Impact of the Dietary Intake of Vitamin B12, Folic Acid, and Vitamin D3 on Homocysteine Levels and the Health-Related Quality of Life of Levodopa-Treated Patients with Parkinson’s Disease—A Pilot Study in Romania

Diagnostics, Journal Year: 2024, Volume and Issue: 14(15), P. 1609 - 1609

Published: July 26, 2024

Previous studies have shown that the levodopa treatment of Parkinson's disease (PD) elevates circulating homocysteine levels, which are associated with an increased risk cardiovascular and neurological disorders, or thrombosis. The present trial aimed to examine whether intake vitamin B12, folic acid, D3 supplements improved level quality life (QoL).

Language: Английский

---

The Imbalance of Homocysteine, Vitamin B12 and Folic Acid in Parkinson Plus Syndromes: A Review beyond Parkinson Disease

Biomolecules, Journal Year: 2024, Volume and Issue: 14(10), P. 1213 - 1213

Published: Sept. 26, 2024

While there is a link between homocysteine (Hcy), B12 and folic acid neurodegeneration, especially in disorders like Parkinson’s Alzheimer’s diseases, its role Parkinson plus syndromes (PPS) has only been partially investigated. It appears that elevated Hcy, along with an imbalance of essential vitamin cofactors, are both implicated the development progression parkinsonian syndromes, which represent different disease pathologies, namely alpha-synucleinopathies tauopathies. Attributing potential pathogenetic hyperhomocysteinemia would be crucial terms improving diagnostic prognostic accuracy these also for providing new target possible therapeutic intervention. The scope this review to focus on PPS, special emphasis neurodegenerative process their implication approach disorders.

Language: Английский

---

Effects of Vitamins on Some Neurological Diseases

Published: June 10, 2024

Vitamins are micronutrients from various food sources that the nervous system needs for proper functioning. Vitamin deficiencies or imbalances can adversely affect neuronal metabolism and lead to neurodegenerative diseases. may have therapeutic properties in Parkinson’s disease thanks their antioxidant anti-inflammatory properties, while water- fat-soluble vitamins help prevent amyloid beta tau pathology Alzheimer’s disease.

Language: Английский

---

Metabolomic and Lipidomic Analysis of Manganese-Associated Parkinsonism: a Case-Control Study in Brescia, Italy

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 6, 2024

Excessive Manganese (Mn) exposure is neurotoxic and can cause Mn-Induced Parkinsonism (MnIP), marked by cognitive motor dysfunction. Although metabolomic lipidomic research in (PD) patients exists, it remains limited. This study hypothesizes distinct profiles based on status, disease diagnosis, their interaction.

Language: Английский

---